Ketamine Dropout Rates: Why Delivery Format Changes Everything

The Dropout Problem in Ketamine Therapy

A new analysis published in Psychiatric Times is drawing attention to a quietly significant problem in the treatment of treatment-resistant depression (TRD): patients are stopping NMDA receptor antagonist therapy—including ketamine and esketamine—at higher rates than clinicians often acknowledge. The report calls on prescribers to move faster, use PHQ-9 scores more aggressively, optimize doses earlier, and switch formulations sooner when side effects are derailing adherence. For patients using ketamine troches at home, this data carries real implications for how you and your provider should be thinking about your own treatment arc.

NMDA receptor antagonists currently approved or widely used for TRD include IV racemic ketamine (off-label), esketamine nasal spray (Spravato, FDA-approved), and compounded ketamine in various forms—most notably sublingual troches. Each carries a distinct side effect burden, and that burden, the Psychiatric Times review makes clear, is a primary driver of who stays in treatment and who doesn't.

What the Side Effect Data Actually Shows

The review breaks down discontinuation and tolerability across the NMDA class. Dissociation, dizziness, nausea, transient blood pressure elevation, and sedation are the most commonly cited reasons patients stop or request dose reductions. Esketamine nasal spray, the only FDA-approved ketamine-adjacent product for TRD, carries a mandatory REMS (Risk Evaluation and Mitigation Strategy) program precisely because of its dissociative and cardiovascular profile—patients must be monitored in-clinic for at least two hours post-dose.

IV ketamine infusions, while not FDA-approved for depression, are administered in clinical settings at doses typically ranging from 0.5 mg/kg over 40 minutes. At those plasma concentrations, dissociative effects are pronounced. Many patients find the experience manageable or even therapeutically meaningful, but a meaningful subset do not—and repeated clinic visits for a dissociative experience create a logistical and psychological barrier that accumulates over time.

Compounded ketamine troches occupy a different place on this spectrum. Sublingual absorption of ketamine yields bioavailability roughly in the 30–35% range, compared to nearly 100% with IV administration. That lower peak plasma concentration isn't a bug for many patients—it's the reason the side effect profile is often described as gentler. Dissociation still occurs at therapeutic troche doses (commonly 100–400 mg), but tends to be milder and shorter-lived than what patients report from infusions. Nausea and cardiovascular changes are generally less pronounced. Crucially, troches are taken at home, on a schedule that integrates into real life rather than requiring repeated clinic visits.

Why Discontinuation Rates Matter More Than They Appear

The Psychiatric Times analysis frames discontinuation as a clinical failure point that receives insufficient systematic attention. When a patient stops an NMDA antagonist due to side effects, the treating clinician often records it as an adverse event—but the downstream consequence is that a patient with TRD remains untreated or undertreated, sometimes for months before a new trial begins.

The authors advocate for what might be called a more dynamic prescribing posture: tracking PHQ-9 scores at every touchpoint, escalating or adjusting doses based on response trajectory rather than waiting for a fixed number of sessions to pass, and switching between formulations—say, from IV infusions to troches, or from esketamine nasal spray to compounded sublingual—when a patient's side effect burden is threatening adherence.

This is not yet standard practice. Many ketamine clinics run protocol-driven infusion series (typically six sessions over two to three weeks) and evaluate response after the fact. Compounding pharmacies and telehealth prescribers working in the troche space have often been more iterative by necessity—patients are dosing at home and reporting back, which creates a different feedback loop. The Psychiatric Times call for faster, data-driven adjustment is, in some ways, already how the troche model operates.

Troches in the Context of the Broader NMDA Class

It's worth situating troches clearly within the landscape the review describes. Ketamine troches are a compounded preparation—not FDA-approved for any indication—which means they exist outside the clinical trial infrastructure that generates the kind of discontinuation rate statistics the article analyzes. The data on esketamine nasal spray comes from robust Phase III trials. IV ketamine data comes from decades of off-label use and a growing observational literature. Troche-specific discontinuation data is sparse and largely anecdotal or drawn from small retrospective studies.

That gap cuts both ways. It means the troche-specific safety and efficacy case is still being built. But it also means that the tolerability advantages troche patients and providers report—lower dissociation intensity, easier home integration, flexible dose titration—haven't been fully stress-tested in large controlled populations. Clinicians recommending troches are drawing on mechanism of action, pharmacokinetic reasoning, and real-world experience rather than head-to-head trial data.

What the Psychiatric Times review implicitly reinforces is that the choice between formulations should be an active clinical decision, revisited regularly, rather than a one-time assignment. A patient who struggled with dissociation on IV infusions is a different candidate than one who found infusions manageable but faces logistical barriers to monthly clinic visits. The troche format may serve each of those patients differently—and the prescriber's job, per this analysis, is to keep asking.

What Patients and Providers Should Do Differently

The practical upshot of the Psychiatric Times analysis, translated to the troche context, comes down to a few actionable principles. First, don't treat your current dose as fixed. Troche prescribers working through telehealth platforms often start conservatively and adjust—but patients need to report side effects and response data clearly for that calibration to happen. Second, understand that mild-to-moderate dissociation at therapeutic troche doses is expected and not necessarily a signal to stop; it's a signal to communicate. Third, if your side effect burden is genuinely limiting your ability to dose consistently, ask your provider explicitly whether a dose reduction, a different troche formulation, or a different timing protocol (morning vs. evening dosing, food timing, adjunctive anti-nausea support) might help.

The review's broader argument—that clinicians should optimize faster and switch sooner—is a rebuke of passive waiting. For patients on troches, that translates to a more active partnership with your prescriber: more frequent check-ins, structured symptom tracking, and a shared understanding that the first protocol you try is a starting point, not a verdict.

Read the full Psychiatric Times analysis here.